A study by Zhang et al in the Journal of Investigative Dermatology pinpoints a neural IL-17 pathway as the driver of psoriatic itch, reshaping how we think about itch in psoriasis. Through a series of ...

Targeting multiple immune mechanisms may overcome therapy resistance and further improve cancer immunotherapy for humans. The authors of a new article published in Acta Pharmaceutica Sinica B describe ...

First-in-human milestone: Zenas BioPharma has dosed the first participant in its Phase 1 trial of ZB021, a novel oral IL-17 inhibitor. Data on horizon: Initial safety and dosing results are ...

A certain biological pathway—a set of linked reactions in the body—drives the inflammation seen in the skin disease psoriasis, a new study finds. The work could lead to improved therapies for all ...

The family of interleukin-17 (IL-17) includes six molecules that respond to infection, in addition to participating in various physiological and pathological processes. A new paper in Signal ...